trial · primary record
Trametinib
Meningioma
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 32 |
| Primary completion | 2028-12-30 |
| Primary endpoint | Dose Limiting Toxicity (DLT) rate of combination Alpelisib and Trametinib |
| Registry ID | NCT03631953 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:46:34.505Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03631953
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Trametinib · approval
- Trametinib · compound